Bragar Eagel & Squire, P.C. Is Investigating Avita, Coty, and Sensus and Encourages Investors to Contact the Firm
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AVITA Medical, Inc. (NASDAQ:RCEL), Coty Inc. (NYSE:COTY), and Sensus Healthcare, Inc. (NASDAQ:SRTS). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
AVITA Medical, Inc. (NASDAQ:RCEL)
On August 7, 2025, Avita released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company’s wound care product, Recell, “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.” As a result, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.”
On this news, the price of AVITA’s shares declined by $1.13 per share, or approximately 21%, from $5.38 per share on August 7, 2025 to close at $4.25 on August 8, 2025.
For more information on the Avita investigation go to: https://bespc.com/cases/RCEL
Coty Inc. (NYSE:COTY)
On August 20, 2025, Coty issued a press release reporting its financial results its full fiscal year 2025 and fourth quarter. Among other items, Coty reported an unexpected loss and provided disappointing guidance. Discussing the results on an earnings call, Coty's Chief Financial Officer said that "[t]he challenges of fiscal year 2025 coincided with moderating profit in the broader beauty market," attributing sluggish sales to factors ranging from value-seeking behavior, innovation fatigue by consumers, and anti-theft and immigration policy changes.
On this news, Coty's stock price fell $1.05 per share, or 21.6%, to close at $3.81 per share on August 21, 2025.
For more information on the Coty investigation go to: https://bespc.com/cases/COTY
Sensus Healthcare, Inc. (NASDAQ:SRTS)
On August 7, 2025, Sensus reported its financial results for the second quarter of 2025, revealing a second quarter GAAP earnings-per-share figure of -$0.06, missing estimates by $0.09, and revenue of $7.3M, representing a -20.7% year-over-year decline and missing estimates by $2M. Sensus attributed the decrease in revenue primarily to a lower number of units sold to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements.
On this news, Sensus's stock price fell $1.89 per share, or 35.32%, to close at $3.46 per share on August 8, 2025.
For more information on the Sensus investigation go to: https://bespc.com/cases/SRTS
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
